

## Review Form 1.7

Journal Name:	<b>Journal of Advances in Medicine and Medical Research</b>
Manuscript Number:	<b>Ms_JAMMR_99735</b>
Title of the Manuscript:	<b>EVALUATION OF THE USE OF ANTIMICROBIALS IN THE TREATMENT OF BACTERIAL PNEUMONIA IN PEDIATRIC PATIENTS AT A TERTIAR HOSPITAL</b>
Type of the Article	<b>Original Research Article</b>

### **General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journaljammr.com/index.php/JAMMR/editorial-policy> )

**Review Form 1.7**

**PART 1: Review Comments**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<p><b>Compulsory</b> REVISION comments</p> <p>1. <b>Is the manuscript important for scientific community?</b> (Please write few sentences on this manuscript)</p> <p>2. <b>Is the title of the article suitable?</b> (If not please suggest an alternative title)</p> <p>3. <b>Is the abstract of the article comprehensive?</b></p> <p>4. <b>Are subsections and structure of the manuscript appropriate?</b></p> <p>5. <b>Do you think the manuscript is scientifically correct?</b></p> <p>6. <b>Are the references sufficient and recent? If you have suggestion of additional references, please mention in the review form.</b></p> <p><b>(Apart from above mentioned 6 points, reviewers are free to provide additional suggestions/comments)</b></p>	<p><b>Yes</b></p> <p><b>Title is fine. There is option for the alternative title as below:</b></p> <p><b>A retrospective cohort analysis of the treatment of Bacterial pneumonia pediatric cases</b></p> <p><b>Yes</b></p> <p>Yes</p> <p>Yes</p> <p>Some references need to look at carefully.</p>	
<p><b>Minor</b> REVISION comments</p> <p>1. <b>Is language/English quality of the article suitable for scholarly communications?</b></p>	<p>English is suitable. Some edits are done by the reviewer.</p>	
<p><b>Optional/General</b> comments</p>	<p>Some more recommendations:</p> <p>This study is based on the prescription of antimicrobials in pneumonia infections in children based on the standardized protocols. I have tried my best to pull up some recommendations. It's better to consult other reviewer who has pure medical background and works on the clinical trials in context with prescribing the antibiotics for the treatment of pneumonia cases.</p> <p>Please find some recommendations as follows:</p> <ol style="list-style-type: none"> <li>Title: Tertiary</li> <li>Rephrase some sentences as below: Place and Duration of Study: The pediatrics sector of the Julio Bandeira University Hospital (HUJB), Brazil from September 2017 to December 2021. Methodology: A total of 734 medical records were analyzed, based on two groups: a) For those subjects who adhered to the protocol (AP) and b) for those who did not (DP), which were already recommended in the agreement described in the guidelines of hospital.</li> <li>Rephrase first and second paragraph of Introduction: Pneumonia is linked to the lower respiratory tract infection and inflammation that can affect both the alveoli and interstitium of lungs. The common manifestations are dyspnea, productive cough, fever and chest pain<sup>1</sup>. This disease acquires attention in the global public health scenario because of high morbidity and mortality across the world, especially in children under 5 years old represented the total of 18% of death cases in the pediatric public<sup>2,3</sup>. In 2017, the disease was responsible for attaining more than 50,000 deaths in children in Brazil and was representing an important cause of hospitalization in same age group of children <sup>4,5</sup>. In addition, it has also drawn the attention in North and Northeast states, which have high mortality rates due to pneumonia<sup>1,6</sup>.</li> <li>Introduction: end of the paragraph 4: Add more reference precisely explain the estimation of WHO regarding mortality comparison.</li> </ol>	

Review Form 1.7

	<p>5. Paragraph 5: Rephrase: Pneumonia caused by the resistant bacteria is difficult to manage clinically, especially in patients who stay longer in hospitals often show worse outcome. Therefore, the targeted antibiotic therapy is fundamentally required for rational use of pharmacological in childhood pneumonia caused by streptococcus pneumoniae.10,12.</p> <p>6. Please add these lines in between paragraph 4 or 5 Introduction: Pediatric infections caused by Streptococcus pneumoniae include otitis media, sinusitis, occult pneumonia, meningitis, bacteremia, osteomyelitis, septic arthritis, peritonitis and pericarditis.</p> <p>7. Material and Methods: Characterization of the study: This retrospective and descriptive cross-sectional study was conducted to evaluate the antibiotic usage in patients hospitalized from 1 September 2017 to 31 December 2021 in the pediatric sector of the Hospital Universitário Júlio Bandeira (HUJB), Cajazeiras-Paraíba, reference for the municipalities of the Ninth Health Region of Paraíba.</p> <p>8. Target Population Samples: Sentences are too lengthy , require little bit changes: The study included patients treated at the pediatrics sector of the Hospital Universitário Júlio Bandeira (children and adolescents aged from 11 months old to 17 years old) diagnosed with pneumonia and who received antibiotic therapy, admitted to the university hospital from September 2017 to December 2021. Data collection was carried out at HUJB through medical prescriptions and electronic medical records available on the Management Application for University Hospitals (AGHU). The data was carefully analyzed and a spreadsheet is prepared containing the following information: antibiotics used; hospitalization time; treatment effectiveness; followed the hospital protocol.</p> <p>9. Tabulated for of the protocol and also mention for pneumonia cases including community acquired pneumonia, atypical pneumonia alongside the cases of Streptococcus pneumoniae.</p> <p>10. Please recheck the protocol and ask other reviewers from medical background.</p> <p>11. Authors have mentioned the drug resistant bacteria so it is imperative to explain the observed antibiotic resistance in patients who followed the treatment regimen fully.</p> <p>12. Please specify the protocol for Pneumonia cases only. Check the time period for pneumonia cases treatment.</p> <p>13. Legionella infection is generally linked to 50+ aged groups. You can mention specifically in discussion if any case found with Legionella and others as multifactorial infection.</p> <p>14. Protocol number or any specific guideline.</p> <p>15. Table 2 and 3: Yes and No should be replaced with patients adhered to the protocol and patient didn't adhere to the protocol.</p> <p>16. Graphical representation of this data will be more visible instead of tables.</p> <p>17. During monotherapy and polytherapy what are the antibiotic resistance patterns observed.</p> <p>18. If authors like to mention of operations and protocols of antibiotic resistance pattern for those patients who haven't shown any improvement.</p> <p>19. Azithromycin is used massively for both AP and DP group. Any noticeable impact.</p> <p>20. If these were not available then you might wish to add more as how can that be contributed to the effective operation.</p> <p>21. It is worthwhile to mention the therapeutic failure in any of patients linked to AP or DP group.</p> <p>22. Little bit changes in some lines below the paragraph "The choice of antibiotic.....cases". Apart from bacterial pneumonia of Streptococcus pneumoniae (pneumococcus), the main etiological agents isolated in patients, prevalent in up to 70% of cases, had been followed by atypical bacteria - Mycoplasma, Legionella and Chlamydia, in approximately 10 to 48% and Haemophilus influenzae in up to 18% of patients.</p> <p>23. Conclusion: Furthermore, the growing use of azithromycin was observed during the years of the Covid-19 pandemic. Please edit couple of more lines as what was the accurate outcome and how it has contributed for the safer treatment. What can be done for further improvements!</p> <p>24. Cited references should be checked twice with text to avoid placing altered information.</p>	
--	---	--

[Review Form 1.7](#)

**PART 2:**

	<b>Reviewer's comment</b>	<b>Author's comment</b> <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
<b>Are there ethical issues in this manuscript?</b>	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

**Reviewer Details:**

Name:	<b>Anju Kaushal</b>
Department, University & Country	<b>New Zealand</b>